Your browser doesn't support javascript.
Cerebrospinal fluid findings in patients with seizure in the setting of COVID-19: A review of the literature.
Carroll, Elizabeth; Melmed, Kara R; Frontera, Jennifer; Placantonakis, Dimitris G; Galetta, Steven; Balcer, Laura; Lewis, Ariane.
  • Carroll E; Department of Neurology, NYU Langone Medical Center, New York, NY, USA. Electronic address: Elizabeth.carroll@nyulangone.org.
  • Melmed KR; Department of Neurology, NYU Langone Medical Center, New York, NY, USA; Department of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
  • Frontera J; Department of Neurology, NYU Langone Medical Center, New York, NY, USA; Department of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
  • Placantonakis DG; Department of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
  • Galetta S; Department of Neurology, NYU Langone Medical Center, New York, NY, USA; Department of Ophthalmology, NYU Langone Medical Center, New York, NY, USA.
  • Balcer L; Department of Neurology, NYU Langone Medical Center, New York, NY, USA; Department of Ophthalmology, NYU Langone Medical Center, New York, NY, USA; Department of Population Health, NYU Langone Medical Center, New York, NY, USA.
  • Lewis A; Department of Neurology, NYU Langone Medical Center, New York, NY, USA; Department of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
Seizure ; 89: 99-106, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1230773
ABSTRACT
We reviewed the literature on cerebrospinal fluid (CSF) studies in patients who had a seizure in the setting of COVID-19 infection to evaluate for evidence of viral neuroinvasion. We performed a systematic review of Medline and Embase to identify publications that reported one or more patients with COVID-19 who had a seizure and had CSF testing preformed. The search ranged from December 1st 2019 to November 18th 2020. We identified 56 publications which described 69 unique patients who met our inclusion criteria. Of the 54 patients whose past medical history was provided, 2 (4%) had epilepsy and 1 (2%) had a prior seizure in the setting of hyperglycemia, but the remaining 51 (94%) had no history of seizures. Seizure was the initial symptom of COVID-19 for 15 (22%) patients. There were 26 (40%) patients who developed status epilepticus. SARS-CoV-2 PCR testing was performed in the CSF for 45 patients; 6 (13%) had a positive CSF SARS-CoV-2 PCR, only 1 (17%) of whom had status epilepticus. The cycle thresholds were not reported. Evaluation for CSF SARS-CoV-2 antibodies (directly or indirectly, via testing for CSF oligoclonal bands or immunoglobulins) was performed in 26 patients, only 2 (8%) of whom had evidence of intrathecal antibody synthesis. Of the 11 patients who had CSF autoimmune antibody panels tested, 1 had NMDA antibodies and 1 had Caspr-2 antibodies. Detection of SARS-CoV-2 in the CSF of patients with seizures who have COVID-19 is uncommon. Our review suggests that seizures in this patient population are not likely due to direct viral invasion of the brain.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Status Epilepticus / COVID-19 Type of study: Experimental Studies / Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Seizure Journal subject: Neurology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Status Epilepticus / COVID-19 Type of study: Experimental Studies / Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Seizure Journal subject: Neurology Year: 2021 Document Type: Article